This site is under development. For the current active site, go to bcbhub.csic.es.

Orcid Publication

Detalle de: Cannabinoid receptor 2 (CB 2 ) agonists and antagonists: a patent update

Title Cannabinoid receptor 2 (CB 2 ) agonists and antagonists: a patent update
Abstract

Introduction Modulation of the CB2 receptor is an interesting approach for pain and inflammation, arthritis, addictions, neuroprotection, and cancer, among other possible therapeutic applications, and is devoid of central side effects. Areas covered This review highlights the novel scaffolds for CB2 ligands and the diverse therapeutic applications for CB2 modulators disclosed in patents published since 2012. Expert opinion Structural diversity of CB2 modulator scaffolds characterized the patent literature. Several CB2 agonists reached clinical Phase II for pain management and inflammation. Other therapeutic applications need to be explored such as neuroprotection and/or neurodegeneration.

Apa Reference Morales, P., Hernandez-Folgado, L., Goya, P. & Jagerovic, N. (2016). Cannabinoid receptor 2 (CB 2 ) agonists and antagonists: a patent update. Expert Opinion on Therapeutic Patents, 26(7), 843-856. 10.1080/13543776.2016.1193157
Doi 10.1080/13543776.2016.1193157
Publication Date 7 Jun 2016
Publication Type Article
Researcher Paula Morales
Ontology Genome Assembly, Molecular Interactions/Docking
Research Groups
Tools

Suggest changes

Publications are synced automatically from ORCID, so they can't be edited here directly. Spotted something wrong? Let us know below and we'll take care of it.

← Return to Home